BIN1 Antibody #13679
- WB
- IP
Supporting Data
| REACTIVITY | H M R |
| SENSITIVITY | Endogenous |
| MW (kDa) | 45-80 |
| SOURCE | Rabbit |
Application Key:
- WB-Western Blotting
- IP-Immunoprecipitation
Species Cross-Reactivity Key:
- H-Human
- M-Mouse
- R-Rat
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:50 |
Storage
Protocol
Specificity / Sensitivity
BIN1 Antibody recognizes endogenous levels of total BIN1 protein. The antibody recognizes multiple BIN1 isoforms and also may cross-react with an unidentified protein of 25 kDa.
Species Reactivity:
Human, Mouse, Rat
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala104 of human BIN1 protein. Antibodies are purified by protein A and peptide affinity chromatography.
Background
Bridging integrator 1 (BIN1, AMPHL) is an adaptor protein and putative tumor suppressor expressed as multiple isoforms due to alternative splicing. The BIN1 protein was originally identified as a Myc box-interacting protein with structural similarity to the synaptic vesicle protein amphiphysin (1). BIN1 protein structure contains an amino-terminal amphipathic helix and a BAR domain that is involved in sensing membrane curvature. The protein also includes a Myc-binding domain and an SH3 domain, which are implicated in protein-protein interactions (1). Multiple BIN1 isoforms range in size from approximately 45 to 65 kDa, with the nuclear BIN1 isoform found mostly in skeletal muscle and the cytoplasmic IIA isoform expressed in axon initial segments and nodes of Ranvier of the brain (2,3). Corresponding BIN1 gene mutations and incorrect splicing can lead to impaired BIN1 membrane-tabulating and protein binding activities, resulting in development of autosomal recessive centronuclear myopathy and myotonic dystrophy (4,5). Genome-wide association studies link the BIN1 gene with late onset Alzheimer disease (AD) and increased BIN1 mRNA expression is seen in AD brains (6,7).
- Sakamuro, D. et al. (1996) Nat Genet 14, 69-77.
- Ge, K. and Prendergast, G.C. (2000) Genomics 67, 210-20.
- Ramjaun, A.R. et al. (1997) J Biol Chem 272, 16700-6.
- Nicot, A.S. et al. (2007) Nat Genet 39, 1134-9.
- Fugier, C. et al. (2011) Nat Med 17, 720-5.
- Seshadri, S. et al. (2010) JAMA 303, 1832-40.
- Chapuis, J. et al. (2013) Mol Psychiatry 18, 1225-34.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.